Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays
- 1 March 2007
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 71 (3) , 893-901
- https://doi.org/10.1124/mol.106.030817
Abstract
HIV-1 integrase binds site-specifically to the ends of the viral cDNA. We used two HIV-1 integrase-DNA cross-linking assays to probe the binding sites of integrase inhibitors from different chemical families and with different strand transfer selectivities. The disulfide assay probes cross-linking between the integrase residue 148 and the 5′-terminal cytosine of the viral cDNA, and the Schiff base assay probes cross-linking between an integrase lysine residue and an abasic site placed at selected positions in the viral cDNA. Cross-linking interference by eight integrase inhibitors shows that the most potent cross-linking inhibitors are 3′-processing inhibitors, indicating that cross-linking assays probe the donor viral cDNA (donor binding site). In contrast, strand transfer-selective inhibitors provide weak cross-linking interference, consistent with their binding to a specific acceptor (cellular DNA) site. Docking and crystal structure studies illustrate specific integrase-inhibitor contacts that prevent cross-linking formation. Four inhibitors that prevented Schiff base cross-linking to the conserved 3′-terminal adenine position were examined for inhibition at various positions within the terminal 21 bases of the viral cDNA. Two of them selectively inhibited upper strand cross-linking, whereas the other two had a more global effect on integrase-DNA binding. These findings have implications for elucidating inhibitor binding sites and mechanisms of action. The cross-linking assays also provide clues to the molecular interactions between integrase and the viral cDNA.Keywords
This publication has 39 references indexed in Scilit:
- Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- HIV‐1 integrase inhibitors: 2003–2004 updateMedicinal Research Reviews, 2006
- Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, Biological Activities, and Mechanism of ActionJournal of Medicinal Chemistry, 2006
- Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymesProceedings of the National Academy of Sciences, 2002
- Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexesThe EMBO Journal, 2001
- The Mobility of an HIV-1 Integrase Active Site Loop Is Correlated with Catalytic Activity,Biochemistry, 1999
- Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interactionThe EMBO Journal, 1998
- HIV inhibitory natural products. 11. Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from a Conospermum spJournal of the American Chemical Society, 1993
- Integration of human immunodeficiency virus DNA: adduct interference analysis of required DNA sites.Proceedings of the National Academy of Sciences, 1992
- Disulfide-crosslinked oligonucleotidesJournal of the American Chemical Society, 1991